0001140361-22-007528.txt : 20220302 0001140361-22-007528.hdr.sgml : 20220302 20220302170104 ACCESSION NUMBER: 0001140361-22-007528 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220224 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SANUWAVE Health, Inc. CENTRAL INDEX KEY: 0001417663 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 201176000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52985 FILM NUMBER: 22704735 BUSINESS ADDRESS: STREET 1: 3360 MARTIN FARM RD STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 770-419-7525 MAIL ADDRESS: STREET 1: 3360 MARTIN FARM RD STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 FORMER COMPANY: FORMER CONFORMED NAME: RUB MUSIC ENTERPRISES, INC. DATE OF NAME CHANGE: 20071106 8-K 1 brhc10034648_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 24, 2022

SANUWAVE HEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)
Nevada
000-52985
20-1176000
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
3360 Martin Farm Road, Suite 100
Suwanee, Georgia 30024
(Address of Principal Executive Offices, Including Zip Code)

(770) 419-7525
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
N/A
N/A
N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-
2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01
Entry into a Material Definitive Agreement.

On February 25, 2022, SANUWAVE Health, Inc., a Nevada corporation (the “Company”) entered into a Second Amendment to Note and Warrant Purchase and Security Agreement (the “Amendment”), which amends that certain Note and Warrant Purchase and Security Agreement, dated as of August 6, 2020 (as amended, the “NWPSA”), with the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent. The Amendment provides for (i) the sale and purchase of incremental secured notes (the “Notes”) in an aggregate original principal amount of $3,000,000, (ii) the issuance of 20,666,993 shares of Common Stock as advisory shares (the “Advisor Shares”) and (iii) the amendment and restatement of the existing warrant (the “Warrant”) issued to the noteholder party to the NWPSA to permit such warrant to be exercisable for an additional 2.0% of the fully-diluted Common Stock of the Company as of the amendment effective date. The warrant has an exercise price of $0.18 per share and a 10 year term from August 6, 2020.

The principal amount outstanding on the Notes shall accrue interest at the per annum rate applicable to the existing notes issued under the NWPSA, which equals the sum of (A) the greater of (x) the Prime Rate (as defined in the NWPSA) in effect as of each interest payment date, and (y) 3.00%, plus (B) 9.00%. All unpaid principal and accrued interest with respect to the Notes are due and payable in full on September 30, 2025. In addition, interest at a per annum rate equal to 3.00% shall be paid in kind.  The Notes are secured by substantially all of the assets of the Company, SANUWAVE, Inc., a Delaware corporation, and their respective domestic subsidiary guarantors.

The NWPSA contains customary representations, warranties, events of default and covenants, including limitations on incurrences of indebtedness and liens, dispositions, distributions, investments, mergers and a minimum liquidity covenant.

The foregoing descriptions of the NWPSA, the Notes and Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the NWPSA, Notes and Warrant, which are filed hereto as Exhibits 10.1, 4.1 and 4.2, respectively, and are incorporated herein by reference.

Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 3.02
Unregistered Sales of Equity Securities.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

The Advisor Shares and Warrant were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
 
 Description
     
 
Secured Promissory Note issued to NH Expansion Credit Fund Holdings LP, dated February 24, 2022.
     
 
Amended and Restated Warrant issued to NH Expansion Credit Fund Holdings LP, dated February 25, 2022.
     
 
Second Amendment to the Note and Warrant Purchase and Security Agreement, dated February 25, 2022, by and among the Company and NH Expansion Credit Fund Holdings LP.
     
104
 
Cover Page Interactive Data File––the cover page XBRL tags are embedded within the Inline XBRL document.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
SANUWAVE HEALTH, INC.
   
Date: March 2, 2022
By:
/s/ Lisa E. Sundstrom
 
   
Lisa E. Sundstrom
   
Chief Financial Officer



EX-4.1 2 brhc10034648_ex4-1.htm EXHIBIT 4.1

Exhibit 4.1

SECURED PROMISSORY NOTE

 $3,000,000.00 
February 24, 2022
      
FOR VALUE RECEIVED,  SANUWAVE HEALTH, INC., a Nevada  corporation (“Issuer”), hereby unconditionally promises to pay to NH EXPANSION CREDIT FUND HOLDINGS LP, a Delaware limited partnership (together with its registered successors and permitted assigns, “Holder”), at the Holder’s lending office, or at such other place as Holder may from time to time designate in writing, in lawful money of the United States of America and in immediately available funds, the principal sum of Three Million Dollars ($3,000,000.00), pursuant to the terms of that certain Note and Warrant Purchase and Security Agreement, dated as of August 6, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “NWPSA”), by and among Issuer, NH EXPANSION CREDIT FUND HOLDINGS LP, as Agent for the noteholders, Holder and each other noteholder from time to time party thereto.  All capitalized terms used herein (which are not otherwise specifically defined herein) shall be used in this Secured Promissory Note (this “Note”) as defined in the NWPSA.

This Note is issued in accordance with the provisions of the NWPSA and is entitled to the benefits and security of the NWPSA and the other Note Documents, and reference is hereby made to the NWPSA for a statement of the terms and conditions under which this Note was made and is required to be repaid.

The outstanding principal balance evidenced by this Note shall be payable in full on the Maturity Date, or on such earlier date as provided for in the NWPSA.

Issuer promises to pay interest from the date hereof until payment in full hereof on the unpaid principal balance of this Note at the per annum rate or rates set forth in the NWPSA.  Interest on the unpaid principal balance of this Note shall be payable on the dates and in the manner set forth in the NWPSA.  Interest as aforesaid shall be calculated in accordance with the terms of the NWPSA.

Upon and after the occurrence of an Event of Default, and as provided in the NWPSA, the principal outstanding under this Note may be declared, and immediately upon such declaration shall become, due and payable without demand, notice or legal process of any kind; provided, however, that upon the occurrence of an Event of Default pursuant to the provisions of Section 7.5(b) or Section 7.5(c) of the NWPSA, the principal outstanding under this Note shall automatically be due and payable, without demand, notice or acceleration of any kind whatsoever.

Payments received in respect of this Note shall be applied as provided in the NWPSA.

Issuer hereby waives presentment, demand, protest and notice of presentment, demand, nonpayment and protest.

No waiver by any Holder of any one or more defaults by Issuer in the performance of any of its obligations under this Note shall operate or be construed as a waiver of any future default or defaults, whether of a like or different nature, or as a waiver of any obligation of Issuer to any other Holder under the NWPSA.

No provision of this Note may be amended, waived or otherwise modified unless such amendment, waiver or other modification is in writing and is signed or otherwise approved by Issuer, Holder and the Required Holders under the NWPSA, to the extent required under Section 11.3 of the NWPSA.

THIS NOTE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES.


Whenever possible each provision of this Note shall be interpreted in such manner as to be effective and valid under applicable law, but in case any provision of or obligation under this Note shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

Whenever in this Note reference is made to Holder or Issuer, such reference shall be deemed to include, as applicable, a reference to their respective successors and permitted assigns.  The provisions of this Note shall be binding upon Issuer and its successors and permitted assigns, and shall inure to the benefit of Holder and its successors and permitted assigns.

In addition to, and without limitation, of any of the foregoing, this Note shall be deemed to be a Note Document and shall otherwise be subject to all of the general terms and conditions contained in Section 8.4 and Article 11 of the NWPSA, mutatis mutandis.

[Signature Page Follows]


IN WITNESS WHEREOF, Issuer has caused this Secured Promissory Note to be executed as of the date first written above.

 
ISSUER:
   
 
SANUWAVE HEALTH, INC.
   
 
By: 
 /s/ Kevin A. Richardson II  
 
Name:
 Kevin A. Richardson II  
 
Title:
 CEO & Chairman  

 
Address for Notice:
 
SANUWAVE HEALTH, INC.
 
11495 Valley View Rd.
 
Eden Prairie MN 55344
 
Attention: Finance

[Signature Page to Secured Promissory Note (Second Closing Note)]



EX-4.2 3 brhc10034648_ex4-2.htm EXHIBIT 4.2

Exhibit 4.2

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
 
AMENDED AND RESTATED
WARRANT TO PURCHASE STOCK
 
Company:
SANUWAVE HEALTH, INC.
Number of Shares:
Set forth below.
Type/Series of Stock:
Common Stock, subject to adjustment as set forth herein
 Warrant Price:
$0.01 per share, subject to adjustment as set forth herein
Issue Date:
August 6, 2020
Expiration Date:
August 6, 2030

Secured Note:
This Amended and Restated Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Note and Warrant Purchase and Security Agreement (as amended from time to time, including by that certain Second Amendment to Note and Warrant Purchase and Security Agreement dated as of February 25, 2022 (the ‘Second Amendment”; collectively, the “Note”), issued as of August 6, 2020, by Sanuwave Health, Inc. (the “Company”) to NH Expansion Credit Fund Holdings LP (the “Noteholder”).
 
THIS WARRANT CERTIFIES THAT, for good and valuable consideration, NH Expansion Credit Fund Holdings LP (“Holder”) is entitled to purchase such number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the Company as is equal to two percent (2.00%) of the Company’s Common Stock on a Fully Diluted Basis (as defined below) as of the Issue Date plus any Post-Closing Adjustment (as defined below), if any, at a price per Share equal to the Warrant Price, which price is subject to adjustment pursuant to Section 2 of this Warrant, and upon the terms and conditions set forth in this Warrant.
 
As of the Second Amendment Effective Date (as defined in the Second Amendment), the Company’s outstanding Common Stock on a Fully Diluted Basis (as defined below) is Seven Hundred Sixty-Four Million Three Hundred Sixty-Three Thousand One Hundred Ten (764,363,110). “Fully Diluted Basis” shall mean the Company’s outstanding common stock including: (i) all common stock, (ii) all preferred stock on an as-converted to common stock basis, (iii) all stock reserved for grant or issuance under the Company’s employee option pool, and assuming the exercise of all convertible notes, if any, warrants and options to purchase stock and the conversion of all rights to purchase stock and any other securities convertible into or exchangeable for Common Stock of the Company. “Post-Closing Adjustment” shall mean any increase in the Company’s outstanding common stock after the Issue Date for which a corresponding adjustment is not already made pursuant to Section 2 due to (i) the issuance of additional shares of common stock pursuant to Section 6.1 of that certain Securities Purchase Agreement by and among the Issuer and the parties thereto dated as of the date hereof (the “Securities Purchase Agreement”), (ii) any increase in the number of shares of common stock for which the warrants issued pursuant to the Securities Purchase Agreement become exercisable, and (iii) any issuance of additional shares of common stock as a result of the conversion to common stock of any convertible note issued on or prior to the Issue Date.

This Warrant amends, restates and replaces in its entirety that certain Warrant to Purchase Stock dated as of August 6, 2020 (the “Original Warrant”).

SECTION 1.        EXERCISE.
 
1.1          Method of Exercise.  Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.
 
1

1.2          Cashless Exercise.  On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised.  Thereupon, the Company shall issue to Holder such number of fully paid and non-assessable Shares as are computed using the following formula:
 
X = Y(A-B)/A

where:
 

X =
the number of Shares to be issued to Holder;
 

Y =
the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
 

A =
the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
 

B =
the Warrant Price.
 
1.3          Fair Market Value.  If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share shall be the daily volume weighted average price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. Notwithstanding the foregoing, if Holder advises the Company in writing that Holder disagrees with such determination, then Company and Holder shall promptly agree upon a reputable investment banking firm to undertake such valuation. If the valuation of such investment banking firm is greater than that determined by the Board of Directors of the Company, then all fees and expenses of such investment banking firm shall be paid by Company.  In all other circumstances, such fees and expenses shall be paid by Holder.
 
1.4          Delivery of Certificate and New Warrant.  Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.
 
1.5       Replacement of Warrant.  On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.
 
1.6          Treatment of Warrant Upon Acquisition of Company.
 
(a)          For the purpose of this Warrant, “Acquisition” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power.
 
2

(b)          In the event of an Acquisition in which (i) the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”) and (ii) the outstanding amounts due under the Notes (as defined in the Purchase Agreement) have been repaid in full prior to or concurrently with such Acquisition, this Warrant shall be automatically deemed exercised pursuant to Section 1.2, effective immediately prior to and contingent upon the consummation of such Acquisition provided that if the sum of the Fair Market Value of the Marketable Securities and Cash payable to Holder is less than the Minimum Cash Value, the Company shall, as a condition to the exercise of the Warrant, subject to the Company having legally available funds, pay Holder in cash the amount of such difference. For purposes of the foregoing sentence, the value of Marketable Securities shall be determined as set forth in 1.3 by reference to the date immediately prior to the date the Acquisition is consummated. “Minimum Cash Value” means the Put Amount (as defined below).
 
(c)          The Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition.  Notwithstanding the foregoing, if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder.
 
(d)       Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the Warrant shall be treated in accordance with Section 1.7.
 
(e)         As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market; and (iii) Holder would be able to publicly re-sell, within six (6) months following the closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition.
 
1.7          Put Option.  At any time after repayment (or other satisfaction of) the Note, but prior to the Expiration Date or any exercise in full of this Warrant, Holder shall have the option to require the Company to, and the Company shall, subject to the Company having legally available funds, immediately upon written request therefor, repurchase this Warrant, for cash in an amount equal to the Put Amount (as defined below). Without limiting the foregoing, in the event of a Change of Control (as defined in the Note), Acquisition and/or acceleration of the Note (whether following an Event of Default (as defined therein) or otherwise), in each case other than a Cash/Public Acquisition in which case the Warrant will be treated in accordance with Section 1.6(b), while the Warrant is outstanding and prior to any exercise in full of this Warrant, the Company shall, subject to the Company having legally available funds, remit to Holder the Put Amount in connection with repayment or other satisfaction of the Note. After remittance of the Put Amount, the Warrant shall be cancelled and of no further force or effect. As used in this Warrant, “Put Amount” means an amount equal to (i) Eight Million Five Hundred Thousand Dollars ($8,500,000.00), multiplied by (ii) the quotient obtained by dividing (x) the number of Shares for which the Warrant is exercisable at such time, by (y) the original maximum number of Shares for which the Warrant was originally exercisable at the time of issuance (as may be adjusted from time to time pursuant to Section 2).
 
3

1.8         Adjustment to Number of Shares, Warrant Price; Adjustments Cumulative.  Upon the Second Amendment Effective Date (as defined in the Second Amendment) this Warrant shall be exercisable, without further action of the Company or Holder, for an additional number of shares equal to two percent (2.00%) of the Company’s outstanding Common Stock on a Fully Diluted Basis as of the Second Amendment Effective Date (such shares, the “Additional Shares”), at a price per Share with respect to such Additional Shares equal to eighteen cents ($0.18), which price is subject to adjustment pursuant to Section 2 of this Warrant, and upon the terms and conditions set forth in this Warrant.
 
SECTION 2.          ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.
 
2.1          Stock Dividends, Splits, Etc.  If the Company declares or pays a dividend or distribution on the outstanding shares of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred.  If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased.  If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.
 
2.2          Reclassification, Exchange, Combinations or Substitution.  Upon any event whereby all of the outstanding shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.  The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.
 
2.3          No Fractional Share.  No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share.  If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the Fair Market Value of a full Share, less (ii) the then-effective Warrant Price.
 
2.4          Notice/Certificate as to Adjustments.  Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based.  The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.
 
SECTION 3.          REPRESENTATIONS AND COVENANTS OF THE COMPANY.
 
3.1          Representations and Warranties.  The Company represents and warrants to, and agrees with, Holder that all Shares which may be issued upon the exercise of this Warrant, shall, effective as of the next equity issuance by the Company after the Issue Date (the “Next Financing Date”), be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.  The Company covenants that it shall, at all times from and after the Next Financing Date, cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant
 
4

3.2          Notice of Certain Events.  If the Company proposes at any time to:
 
(a)          declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;
 
(b)          offer for subscription or sale pro rata to Holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); or
 
(c)          effect an Acquisition or to liquidate, dissolve or wind up;
 
then, in connection with each such event, the Company shall give Holder:
 
(1)          at least ten (10) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and
 
(2)            in the case of the matters referred to in (c) above at least ten (10) Business Days prior written notice of the date when the same will take place (and specifying the date on which Holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event).
 
3.3          Information Rights.  So long as the Holder holds this Warrant and/or any of the Shares, the Company shall deliver to the Holder (a) within ninety (90) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company and (b) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements, provided that Company need not provide such information for any period in which Company has filed Form 10K or Form 10Q (as applicable) with the Securities and Exchange Commission or for any period for which financial statements were provided to Noteholder pursuant to the Note.
 
SECTION 4.          REPRESENTATIONS, WARRANTIES OF HOLDER.
 
Holder represents and warrants to the Company as follows:
 
4.1          Purchase for Own Account.  This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act.  Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.
 
4.2          Disclosure of Information.  Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities.  Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.
 
4.3          Investment Experience.  Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk.  Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.
 
5

4.4          Accredited Investor Status.  Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.
 
4.5          The Act.  Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Holder’s investment intent as expressed herein.  Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available.  Holder is aware of the provisions of Rule 144 promulgated under the Act.
 
4.6          No Voting Rights.  Holder, as a holder of this Warrant, will not have any voting rights until the exercise of this Warrant.
 
SECTION 5.          MISCELLANEOUS.
 
5.1          Term and Automatic Conversion Upon Expiration.
 
(a)          Term.  Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00 PM, Pacific Time, on the Expiration Date and shall be void thereafter.
 
(b)          Automatic Cashless Exercise upon Expiration.  This Warrant shall automatically be deemed exercised on and as of the Expiration Date pursuant to Section 1.2 above as to all Shares, and the Company shall, within 5 Business Days, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder, together with any cash payment required pursuant to Section 2.5.
 
5.2          Legends.  The Shares shall be imprinted with a legend in substantially the following form:
 
THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
 
5.3          Compliance with Securities Laws on Transfer.  This Warrant and the Shares issuable upon exercise of this Warrant may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee.  The Company shall not require Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act.  Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act.
 
5.4          Transfer Procedure.  Holder may transfer this Warrant to an affiliate and such affiliate may make subsequent assignments to its affiliates.  By its acceptance of this Warrant, any affiliate of Holder, and any affiliate to which this Warrant is subsequently transferred, makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof.  Subject to the provisions of Section 5.3, any Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant to any non-affiliated transferee, provided, however, in connection with any such transfer, Holder will give the Company notice of such transfer with the name, address and taxpayer identification number of the non-affiliated transferee and, at the Company’s request, will surrender the Warrant or Shares, as applicable, to the Company for reissuance to the non-affiliated transferee(s); and provided further, that any subsequent non-affiliated transferee shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant.
 
6

5.5          Notices.  All notices and other communications hereunder from the Company to Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5.  All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:
 
 NH Expansion Credit Fund Holdings LP
 1585 Broadway, 39th Floor
 New York, NY 10036
 Attn: Debra Abramovitz

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:
 
 SANUWAVE HEALTH, INC.
 11495 Valley View Rd.
 Eden Prairie MN 55344
 Attention: Finance

5.6          Waiver.  This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.
 
5.7          Attorneys’ Fees.  In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.
 
5.8       Counterparts; Facsimile/Electronic Signatures.  This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement.  Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.
 
5.9         Governing Law.  This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles regarding conflicts of law.
 
5.10        Headings.  The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant.
 
5.11         Business Days.  “Business Day” is any day that is not a Saturday, Sunday or a day on which banks in New York City are closed.
 
5.12         Effective of Amendment and Restatement. This Warrant amends and restates in its entirety, and replaces, the Original Warrant.

 [Balance of Page Intentionally Left Blank]

7

IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.
 
“COMPANY”
 
   
SANUWAVE HEALTH, INC.
 
   
By:
 /s/ Kevin A Richardson II
 

 
Name:
Kevin A Richardson II
 
     
Title:
CEO & Chairman
 
   
“HOLDER”
 
   
NH EXPANSION CREDIT  FUND HOLDINGS LP
 
   
By: MS Expansion Credit GP L.P., its general partner  
By: MS Expansion Credit GP Inc., its general partner  

 
By:
/s/ William Reiland
 

 
Name:
William Reiland
 
   
Title:
Managing Director
 

[Signature Page to Amended and Restated Warrant to Purchase Stock]


APPENDIX 1

NOTICE OF EXERCISE
 
1.          The undersigned Holder hereby exercises its right to purchase ___________ shares of the Common/Series ______ Preferred [circle one] Stock of Sanuwave Health, Inc. (the “Company”) in accordance with the attached Amended and Restated Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:
 
[    ]          check in the amount of $________ payable to order of the Company enclosed herewith
 
[    ]          Wire transfer of immediately available funds to the Company’s account
 
[    ]          Cashless Exercise pursuant to Section 1.2 of the Warrant
 
[    ]          Other [Describe] __________________________________________
 
2.          Attached is a calculation of any adjustment to the number of Shares in accordance with Section 2.6.
 
3.          Please issue a certificate or certificates representing the Shares in the name specified below:


Holder’s Name




(Address)
 
4.          By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Amended and Restated Warrant to Purchase Stock as of the date hereof.
 
 
HOLDER:
   
     
 
By:
 
   
 
Name:
 
   
 
Title:
 
   
 
Date:
 



EX-10.1 4 brhc10034648_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

SECOND AMENDMENT TO NOTE AND WARRANT PURCHASE AND SECURITY AGREEMENT
 
This Second Amendment to Note and Warrant Purchase and Security Agreement (this “Amendment”) is entered into as of February 25, 2022, by and among NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent (in such capacity, together with its successors or permitted assigns, “Agent”), the Holders from time to time signatory to the NPA (as hereinafter defined), including North Haven Expansion (each, a “Holder” and collectively, the “Holders”), and SANUWAVE HEALTH, INC. a Nevada corporation (“Issuer”).
 
RECITALS
 
WHEREAS, Issuer, Agent and the Holders are parties to that certain Note and Warrant Purchase and Security Agreement dated as of August 6, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “NPA”).
 
WHEREAS, Issuer is in default of the NPA as described below;
 
WHEREAS, Issuer has requested that Agent and the Holders amend the NPA to (i) forbear from exercising remedies under the NPA as a result of the Existing Defaults (as hereafter defined) and (ii) advance to Issuer an additional Note (as hereafter described);
 
WHEREAS, Agent and the Holders have agreed to so amend certain provisions of the NPA, and to so forbear from exercising Agent’s and the Holders’ rights and remedies during the Forbearance Period (as defined below), but only to the extent in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below; and
 
WHEREAS, all terms not otherwise defined herein and defined in the NPA shall have the same meanings herein as in the NPA.
 
NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto hereby agree as follows:
 
1.           Certain Events of Default have occurred and continue under the NPA, as more particularly described on Annex ED attached hereto (collectively, the “Existing Defaults”).  Subject to the terms of this Amendment, Agent and the Holders shall forbear from exercising their remedies arising out of the Existing Defaults from the date hereof (including, for the avoidance of doubt, the collection in cash or payment in kind of the Default Rate on the outstanding Obligations under the NPA and the other Note Documents), until the earlier to occur of (x) the occurrence of an Event of Default after the date hereof, at which time Agent and the Holders may exercise any and all rights available to them without notice to Issuer; or (y) June 30, 2022.  Agent and the Holders do not forbear from exercising their remedies arising out of any other Events of Default that have occurred, are continuing or may occur on or after the Second Amendment Effective Date. Issuer shall comply with all other provisions of the NPA and the other Note Documents.
 
2.           Section 1.1(a) of the NPA hereby is renumbered as Section 1.1(a)(i), and new Section 1.1(a)(ii) hereby is added to the NPA to read as follows:
 
“(ii)           Second Closing.  On or about the Second Amendment Effective Date, or as soon thereafter as practical, subject to satisfaction of the terms and conditions set forth in this Agreement, the Holders shall purchase a Note in an original principal amount of Three Million Dollars ($3,000,000) (the “Second Closing Note”), and an Amended and Restated Warrant to Purchase Stock, on terms, and subject to adjustments as set forth therein (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Second Closing Warrant”).
 
3.          A new Section 5.2(h) hereby is added to the NPA to read as follows:


 “(h)          Notwithstanding any other provision of Section 5.2(a) to the contrary, deliver to Agent, within two (2) Business Days’ thereof, evidence of the following: (i) filing of the 10-Q for the period ending September 30, 2021 by February 28, 2022; (ii) filing of the 10-K for the period ending December 31, 2021 by May 15, 2022; (iii) filing of the 10-Q for the fiscal quarter ending March 31, 2022 by May 31, 2022 and (iv) filing of all other 10-Q and 10-K reports for fiscal year 2022 prior to SEC filing deadlines.”
 
4.           Section 5.9 of the NPA hereby is amended and restated in its entirety to read as follows:
 
5.9           Use of Proceeds. Issuer shall use the proceeds of the Notes: (i) as working capital and to fund its general corporate and business requirements and not for personal, family, household or agricultural purposes, (ii) to repay the Existing Indebtedness in full on the Issue Date, (iii) to finance a portion of the Celularity Acquisition and (iv) in the case of proceeds of the Second Closing Note, in accordance with a budget for the projected use of the proceeds from and after the Second Amendment Effective Date, as reviewed and approved in writing by Agent (the “Budgeted Use of Proceeds”).”
 
5.           Section 11.6 of the NPA hereby is renumbered to “11.6.1,” and re-titled “Purchase Price Allocation – First Closing Note;” and a new Section 11.6.2 hereby is added to the NPA to read as follows:
 
11.6.2      Purchase Price Allocation – Second Closing Note.  Issuer and each Holder acknowledge and agree that the Second Closing Note and the Second Closing Warrant are part of an investment unit within the meaning of Section 1273(c)(2) of the IRC.  Issuer and each Holder further agree as between them, that the fair market value of the Second Closing Warrant is Two Million Forty-Three Thousand Five Hundred Sixteen Dollars $(2,043,516) and that, pursuant to Treas.  Reg.  § 1.1273-2(h), Two Million Forty-Three Thousand Five Hundred Sixteen Dollars $(2,043,516) of the issue price of the investment unit will be allocable to such Second Closing Warrant and the balance shall be allocable to such Second Closing Note.  Issuer and each Holder agree to prepare their federal income tax returns in a manner consistent with the foregoing.  Issuer agrees that it shall not (and shall cause its Subsidiaries not to) challenge or support any challenge to the agreed-upon value of such Second Closing Warrant.”
 
6.           The following definitions hereby are added to Section 13.1 of the NPA as follows:
 
Advisor Shares” means Twenty Million Six Hundred Sixty-Six Thousand Nine Hundred Ninety-Three (20,666,993) shares of Issuer’s common stock, issued without cost to Agent, as a result of Agent’s role as an advisor to Issuer.
 
Budgeted Use of Proceeds” has the meaning ascribed in Section 5.9.
 
Second Amendment Effective Date” means February 25, 2022.
 
Second Closing Note” has the meaning ascribed in Section 1.1(a)(ii).
 
Second Closing Warrant” has the meaning ascribed in Section 1.1(a)(ii).
 
7.           Schedule 1.1 to the NPA hereby is replaced in its entirety with Schedule 1.1 attached hereto.
 
8.           No course of dealing on the part of Agent or the Holders or their respective officers, nor any failure or delay in the exercise of any right by Agent or the Holders, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right except as specially waived herein.  Except as specifically waived herein, Agent’s or any Holder’s failure at any time to require strict compliance by Issuer of any provision under the NPA, shall not affect any right of Agent or the Holders under the NPA thereafter to demand strict compliance.  Any suspension or waiver of a right must be in writing signed by an officer of Agent or the Holders, as applicable.
 
9.           The NPA, as amended hereby, shall be and remain in full force and effect in accordance with their respective terms and hereby are ratified and confirmed in all respects.  Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Agent or the Holders under the NPA, as in effect prior to the date hereof.
 

10.        Issuer hereby represents and warrants that (a) the representations and warranties in the NPA, shall be true, accurate, and complete in all material respects immediately after giving effect to this Amendment; provided, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof, which representations and warranties shall be true, accurate and complete immediately after giving effect to this Amendment in all respects subject to such qualification; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, (b) other than the Existing Defaults, no Default or Event of Default shall have occurred and be continuing immediately after giving effect to this Amendment, (c) Issuer has the power and authority to execute and deliver this Amendment and to perform its obligations under the NPA, as amended by this Amendment, (d) the execution and delivery by Issuer of this Amendment and the performance by Issuer of its obligations under the NPA, as amended by this Amendment, have been duly authorized by Issuer, (e) the execution and delivery by Issuer of this Amendment and the performance by Issuer of its obligations under the NPA, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Issuer, (ii) any contractual restriction with a Person binding on Issuer, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Issuer, or (iv) the organizational documents of Issuer, (f) the execution and delivery by Issuer of this Amendment and the performance by Issuer of its obligations under the NPA, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Issuer, except as already has been obtained or made, and (g) this Amendment has been duly executed and delivered by Issuer and is the binding obligation of Issuer, enforceable against Issuer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
 
11.         Release by Issuer.
 
A.           FOR GOOD AND VALUABLE CONSIDERATION, Issuer hereby forever relieves, releases, and discharges Agent, the Holders and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution of this Amendment (collectively, the “Released Claims”).  Without limiting the foregoing, the Released Claims shall include any and all liabilities or claims arising out of or in any manner whatsoever connected with or related to the Note Documents, the recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and/or enforcement of any of the foregoing, in each case existing or arising on or prior to the date of this Amendment.
 
B.            In furtherance of this release, Issuer expressly acknowledges and waives any and all rights under Section 1542 of the California Civil Code (or its equivalent under New York law), which provides as follows:
 
“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”
 

C.            By entering into this release, Issuer recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Issuer hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected; accordingly, if Issuer should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Issuer shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever.  Issuer acknowledges that it is not relying upon and has not relied upon any representation or statement made by Agent or the Holders with respect to the facts underlying this release or with regard to any of such party’s rights or asserted rights.
 
D.            This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release.  Issuer acknowledges that the release contained herein constitutes a material inducement to Agent and the Holders to enter into this Amendment, and that Agent and the Holders would not have done so but for their expectation that such release is valid and enforceable in all events.
 
E.              Issuer hereby represents and warrants to Agent and the Holders, and Agent and the Holders are relying thereon, as follows:
 
1.     Except as expressly stated in this Amendment, neither Agent or the Holders nor any agent, employee or representative of Agent or the Holders has made any statement or representation to Issuer regarding any fact relied upon by Issuer in entering into this Amendment.
 
2.       Issuer has made such investigation of the facts pertaining to this Amendment and all of the matters appertaining thereto, as it deems necessary.
 
3.      The terms of this Amendment are contractual and not a mere recital.
 
4.     This Amendment has been carefully read by Issuer, the contents hereof are known and understood by Issuer, and this Amendment is signed freely, and without duress, by Issuer.
 
5.        Issuer hereby represents and warrants that it is the sole and lawful owner of all right, title and interest in and to every claim and every other matter which it releases herein, and that it has not heretofore assigned or transferred, or purported to assign or transfer, to any person, firm or entity any claims or other matters herein released.  Issuer shall indemnify, defend and hold harmless Agent and Holders from and against all claims based upon or arising in connection with prior assignments or purported assignments or transfers of any claims or matters released herein.
 
12.         As a condition to the effectiveness of this Amendment, Agent shall have received, in form and substance reasonably satisfactory to Agent, the following:
 
(a)          this Amendment, duly executed by Issuer;
 
(b)        a completed Issuer Resolutions and Incumbency, with all exhibits, as of the Second Amendment Effective Date, in substantially the form attached hereto;
 
(c)          the Second Closing Note, in substantially the form attached hereto;
 
(d)          the Second Closing Warrant;
 
(e)          An Affirmation of Unconditional Guaranty and Third Party Security Agreement, duly executed by the parties thereto;
 
(f)          an Affirmation Intercreditor Agreement, in substantially the form attached hereto;
 
(g)          the Budgeted Use of Proceeds;
 

(h)         all Holder Expenses incurred through the date of this Amendment, which shall be wired to Agent’s and Holder’s counsel on the date hereof in accordance with the wire instructions attached hereto as Supplement I; and
 
(i)         such other documents, and completion of such other matters, as Agent or Holder may reasonably deem necessary or appropriate.
 
13.        As conditions subsequent to the effectiveness of this Amendment, Agent shall have received, in form and substance reasonably satisfactory to Agent, the following by the respective dates (the failure timely to achieve of any of which shall constitute an immediate and non-curable Event of Default):
 
13.1           Evidence of Issuer’s receipt, on or before February 28, 2022, of net proceeds of at least Seven Hundred Twenty-Five Thousand Dollars ($725,000.00) from an initial closing under the Asset Purchase Agreement (the “Initial APA Closing”);
 
13.2           Evidence of Issuer’s receipt, on or before April 15, 2022, of net proceeds of at least One Million Dollars ($1,000,000.00) from a subsequent closing (including the proceeds received in the Initial APA Closing) under the Asset Purchase Agreement; and
 
13.3           Evidence of (i) Issuer’s receipt of net proceeds of at least Seven Million Five Hundred Thousand Dollars ($7,500,000.00) from the sale and issuance of Issuer’s equity securities, on terms and conditions reasonably acceptable to Agent (the “May 2022 Equity Raise”); and (ii) satisfaction in full of the Indebtedness owing Leviston Resources, LLC under the Future Advance Convertible Promissory Note dated April 20, 2021 in the original principal amount of up to $3,402,000, from the proceeds of the May 2022 Equity Raise; in each case, on or before May 1, 2022; and
 
13.4           The Advisor Shares, by no later than March 4, 2022; provided that Issuer shall cause the Advisor Shares to be registered on Form S-1, and thereafter freely tradeable, no later than June 30, 2022, provided that Issuer shall cause to be filed with the Securities and Exchange Commission (“SEC”) no later than June 30, 2022, a Registration Statement on Form S-1 for the resale of the Advisor Shares, and shall use its best efforts to have the Form S-1 declared effective by the SEC as soon as possible thereafter.
 
14.         Section 10 of the NPA hereby is incorporated herein by this reference as though fully set forth herein.
 
15.         This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, are an original, and all taken together, constitute one Amendment.
 
[Balance of Page Intentionally Left Blank]
 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.

 
COMPANY:
   
  SANUWAVE HEALTH, INC.
   
 
By:/s/ Kevin A. Richardson II
 
Name: Kevin A. Richardson II
 
Title: CEO & Chairman

[Signature Page to Second Amendment to Note and Warrant Purchase and Security Agreement]
 
[Signatures Continued, Next Page]
 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.
 
  AGENT AND HOLDER:
   
 
NH EXPANSION CREDIT FUND HOLDINGS LP
   
  By: MS Expansion Credit GP, L.P.
  Its: General Partner
   
  By: MS Expansion Credit GP Inc.
  Its: General Partner
   
  By: /s/ William Reiland
  Name: William Reiland
 
Title: Managing Director

[Signature Page to First Amendment to Note and Warrant Purchase and Security Agreement]
 

ANNEX ED
(Existing Defaults)
 
NPA Section:
As a result of:
7.2(a)
Failure timely to deliver financial
reporting required under Section  5.2
of the NPA
   
7.2(a)
Failure to maintain at all times
minimum Liquidity of $5,000,000
as required under Section 6.5 of the
NPA
   
7.5
As a result of Issuer’s failure to pay
its debts, including trade debts, when
due
   
7.6
As a result of Issuer’s default of
other agreements; failure to pay
Indebtedness at maturity
(Cellularity, et al)
   


SCHEDULE 1.1
 
Holders and Commitments
 
First Closing Note:
 
   
Lender
Commitment Amount
Commitment Percentage
NH EXPANSION CREDIT FUND HOLDINGS LP
$15,000,000.00
100.00%
TOTAL
$15,000,000.00
100.00%

Second Closing Note:
 
   
Lender
Commitment Amount
Commitment Percentage
NH EXPANSION CREDIT FUND HOLDINGS LP
$3,000,000.00
100.00%
TOTAL
$3,000,000.00
100.00%

Total:
     
Lender
Commitment Amount
Commitment Percentage
NH EXPANSION CREDIT FUND HOLDINGS LP
$18,000,000.00
100.00%
TOTAL
$18,000,000.00
100.00%


SECURED PROMISSORY NOTE
[Second Closing Note]

 $3,000,000.00 
 February 25, 2022
                  
FOR VALUE RECEIVED,  SANUWAVE HEALTH, INC., a Nevada  corporation (“Issuer”), hereby unconditionally promises to pay to NH EXPANSION CREDIT FUND HOLDINGS LP, a Delaware limited partnership (together with its registered successors and permitted assigns, “Holder”), at the Holder’s lending office, or at such other place as Holder may from time to time designate in writing, in lawful money of the United States of America and in immediately available funds, the principal sum of Three Million Dollars ($3,000,000.00), pursuant to the terms of that certain Note and Warrant Purchase and Security Agreement, dated as of August 6, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “NWPSA”), by and among Issuer, NH EXPANSION CREDIT FUND HOLDINGS LP, as Agent for the noteholders, Holder and each other noteholder from time to time party thereto.  All capitalized terms used herein (which are not otherwise specifically defined herein) shall be used in this Secured Promissory Note (this “Note”) as defined in the NWPSA.

This Note is issued in accordance with the provisions of the NWPSA and is entitled to the benefits and security of the NWPSA and the other Note Documents, and reference is hereby made to the NWPSA for a statement of the terms and conditions under which this Note was made and is required to be repaid.

The outstanding principal balance evidenced by this Note shall be payable in full on the Maturity Date, or on such earlier date as provided for in the NWPSA.

Issuer promises to pay interest from the date hereof until payment in full hereof on the unpaid principal balance of this Note at the per annum rate or rates set forth in the NWPSA.  Interest on the unpaid principal balance of this Note shall be payable on the dates and in the manner set forth in the NWPSA.  Interest as aforesaid shall be calculated in accordance with the terms of the NWPSA.

Upon and after the occurrence of an Event of Default, and as provided in the NWPSA, the principal outstanding under this Note may be declared, and immediately upon such declaration shall become, due and payable without demand, notice or legal process of any kind; provided, however, that upon the occurrence of an Event of Default pursuant to the provisions of Section 7.5(b) or Section 7.5(c) of the NWPSA, the principal outstanding under this Note shall automatically be due and payable, without demand, notice or acceleration of any kind whatsoever.

Payments received in respect of this Note shall be applied as provided in the NWPSA.

Issuer hereby waives presentment, demand, protest and notice of presentment, demand, nonpayment and protest.

No waiver by any Holder of any one or more defaults by Issuer in the performance of any of its obligations under this Note shall operate or be construed as a waiver of any future default or defaults, whether of a like or different nature, or as a waiver of any obligation of Issuer to any other Holder under the NWPSA.

No provision of this Note may be amended, waived or otherwise modified unless such amendment, waiver or other modification is in writing and is signed or otherwise approved by Issuer, Holder and the Required Holders under the NWPSA, to the extent required under Section 11.3 of the NWPSA.

THIS NOTE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES.


Whenever possible each provision of this Note shall be interpreted in such manner as to be effective and valid under applicable law, but in case any provision of or obligation under this Note shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

Whenever in this Note reference is made to Holder or Issuer, such reference shall be deemed to include, as applicable, a reference to their respective successors and permitted assigns.  The provisions of this Note shall be binding upon Issuer and its successors and permitted assigns, and shall inure to the benefit of Holder and its successors and permitted assigns.

In addition to, and without limitation, of any of the foregoing, this Note shall be deemed to be a Note Document and shall otherwise be subject to all of the general terms and conditions contained in Section 8.4 and Article 11 of the NWPSA, mutatis mutandis.

[Signature Page Follows]


IN WITNESS WHEREOF, Issuer has caused this Secured Promissory Note to be executed as of the date first written above.
 
 
ISSUER:
   
 
SANUWAVE HEALTH, INC.
   
 
By
 
 
Name:
 
 
Title:
 
   
 
Address for Notice:
 
SANUWAVE HEALTH, INC.
   
   
 
Attn:
 
 
Email:
 

[Signature Page to Secured Promissory Note (Second Closing Note)]


AFFIRMATION OF UNCONDITIONAL GUARANTY AND THird PArty SECURITY AGREEMENT
February __, 2002
 
Each of the undersigned hereby ratifies and confirms that certain Unconditional Guaranty (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty”), and that certain Third Party Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), each dated as of August 6, 2020 (collectively, the “Guaranty Documents”), executed and delivered to NH EXPANSION CREDIT FUND HOLDINGS LP as agent (in such capacity, together with its successors and permitted assigns, “Agent”) on behalf of the Holders (as defined therein), pursuant to which the undersigned guaranteed certain present and future indebtedness of SANUWAVE HEALTH, INC., a Nevada corporation (“Issuer”), in accordance with the terms contained in said Guaranty Documents, and represents and warrants to Agent as follows:
 

1.
that said Guaranty Documents remain in full force and effect, are valid and binding in accordance with their terms, and that the undersigned have no defenses to the enforceability thereof;
 

2.
that said Guaranty Documents run in favor of Agent; and
 

3.
that pursuant to that certain Second Amendment to Note and Warrant Purchase and Security Agreement dated as of the date hereof, which amends that certain Note and Warrant Purchase and Security Agreement, dated as of August 6, 2020 (as may be otherwise amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “NPA”), Holders, amongst other things, have purchased from Issuer that certain Promissory Note in the original principal amount of Three Million Dollars ($3,000,000.00).
 
The undersigned has obtained such information as it desires as to the affairs of Issuer and understands that Agent has no duty or obligation, now or in the future, to supply the undersigned with any information whatsoever concerning Issuer. The undersigned furthermore understands and agrees that the giving of this affirmation at this time does not create an obligation on Agent to obtain an affirmation in the future or effect the terms of the Guaranty Documents as expressed therein, and that the failure of Agent to obtain such an affirmation in the future shall not at any time affect the validity or scope of the Guaranty Documents, including but not limited to any future amendment of any of the Loan Documents (as such term is defined in the NPA).
 
In all other respects, as set forth above, the Guaranty Documents are hereby ratified and affirmed.

[Balance of Page Intentionally Left Blank]
 

IN WITNESS WHEREOF, each undersigned Guarantor has executed this Affirmation of Unconditional Guaranty and Third Party Security Agreement, intending to be legally bound hereby, as of the date first set forth above.
 
SANUWAVE, INC.

By:
   

Name:
   
   
Title:
   

SANUWAVE SERVICES, LLC

By:
   

Name:
   
   
Title:
   


AFFIRMATION OF INTERCREDITOR AGREEMENT
 
This Affirmation of Intercreditor Agreement (this “Affirmation”) is executed by and between Goodman Capital Finance, a division of Independent Bank (together with its successors and permitted assigns, “Senior Creditor”), and NH Expansion Credit Fund Holdings LP, as Agent for the Holders (under and as defined in the Junior Creditor Documents (as defined below)) (together with its successors and permitted assigns, “Junior Creditor”), as of February 25, 2022. Capitalized terms used without definitions herein shall have the definitions ascribed in the Intercreditor Agreement (as hereafter defined).
 
A.          WHEREAS, Senior Creditor and Junior Creditor are parties to that certain Intercreditor Agreement dated as of June 8, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Intercreditor Agreement”).
 
B.          WHEREAS, Junior Creditor and Debtor are entering into that certain Second Amendment to Note and Warrant Purchase and Security Agreement (the “Amendment”) as of February 25, 2022, with respect to which, among other things, Junior Creditor is purchasing from Debtor that Second Closing Note (as defined in the Amendment), in the original principal amount of Three Million Dollars ($3,000,000.00).
 
NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
 
1.          The Intercreditor Agreement is and shall remain in full force and effect.
 
2.          Senior Creditor hereby consents to the execution, delivery and performance by Junior Creditor and Debtor of the Amendment and the documents and instruments executed and/or delivered in connection therewith.
 
3.          Senior Creditor acknowledges and agrees that the obligations of Issuer to Junior Creditor, as modified by the Amendment, constitute Junior Debt, and that the Amendment constitutes a Junior Creditor Document, for all purposes of the Intercreditor Agreement.
 
4.          This Affirmation may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “pdf’ signature page were an original hereof.
 
[Balance of Page Intentionally Left Blank]
 

IN WITNESS WHEREOF, the parties hereto have caused this Affirmation to Intercreditor Agreement to be duly executed as of the day and year first above written.
 
 
SENIOR CREDITOR
   
 
GOODMAN CAPITAL FINANCE,
 
A DIVISION OF INDEPENDENT BANK
   
 
By:
   
 
Title:
   
     
 
Address: 3010 LBJ Freeway, Suite 140
 
               Dallas, TX 75234
 
Attention:
   
 
Fax:
   
     
 
JUNIOR CREDITOR
   
 
NH EXPANSION CREDIT FUND HOLDINGS LP
   
 
By: MS Expansion Credit GP, L.P.
 
Its: General Partner
   
 
By: MS Expansion Credit GP Inc.
 
Its: General Partner
     
 
By
   
 
Name:William Reiland
 
Title:   Managing Director
   
 
Address:
 
1585 Broadway, 39th Floor
 
New York, NY 10036
 
Attn: Debra Abramovitz
 
Expansion_credit_reporting@morganstanley.com

[Signature Page to Affirmation of Intercreditor Agreement]


ISSUER RESOLUTIONS
 
CORPORATE CERTIFICATE
 
Issuer: SANUWAVE HEALTH, INC.
  Date: February 25, 2022
Holder: NH EXPANSION CREDIT FUND HOLDINGS LP
 
       
I hereby certify as follows, as of the date set forth above:
 

1.
I am the Secretary, Assistant Secretary or other officer of the Issuer.  My title is as set forth below.
 

2.
Issuer’s exact legal name is set forth above.  Issuer is a corporation existing under the laws of the State of Delaware.
 

3.
Attached hereto as Exhibit 1 is a true, correct and complete copy of Issuer’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the State of Delaware.  Such Certificate of Incorporation has not been amended, annulled, rescinded, revoked or supplemented, and remains in full force and effect as of the date hereof.
 

4.
Attached hereto as Exhibit 2 is a true, correct and complete copy of Issuer’s Bylaws (including amendments), which Bylaws have not been amended, annulled, rescinded, revoked or supplemented, and remain in full force and effect as of the date hereof.
 

5.
The following resolutions were duly and validly adopted by Issuer’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).  Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Holder may rely on them until Holder receives written notice of revocation from Issuer.
 

Resolved, that any one of the following officers or employees of Issuer, whose names, titles and signatures are below, may act on behalf of Issuer:
 
Name
 
Title
 
Signature
Authorized to
Add or Remove
Signatories
           
         
           
         
           
         
           
         

Resolved Further
, that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Issuer.
 
Resolved Further, that such individuals may, on behalf of Issuer:
 
Execute Note Documents.  Execute the Second Amendment to Note and Warrant Purchase and Security Agreement, dated as of February __, 2002, which amends the Note and Warrant Purchase and Security Agreement dated as of August 6, 2020, between Holder and Issuer (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “NWPSA”), and any other Note Documents (as defined in the NWPSA) that Holder requires.
Grant Security.  Grant Holder a security interest in any of Issuer’s assets.
Subsidiary Collateral. Cause certain subsidiaries to provide guaranties of the obligations, which may be secured.
Issue Warrants.  Issue warrants for Issuer’s capital stock.
Further Acts.  Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Issuers right to a jury trial) they believe to be necessary to effectuate such resolutions.

[Balance of Page Intentionally Left Blank]
 

Resolved Further, that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.
 

6.
The persons listed above are Issuer’s officers or employees with their titles and signatures shown next to their names.
 
 
By:
   
 
Name:
   
 
Title:
   

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 6 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Issuer.
 
I, the ________________________ of Issuer, hereby certify as to paragraphs 1 through 6 above, as
[print title]
of the date set forth above.
 
 
By:
   
 
Name:
   
 
Title:
   

 [Signature Page to Issuer Resolutions]


Exhibit 1
Certificate of Incorporation (including amendments)


Exhibit 2
Bylaws (including amendments)
 

SUPPLEMENT I
(Wire Instructions)
 
Agent’s and Holders’ counsel fees in the amount of $28,588.00 shall be wired as follows:

Bank Name:
 
SWIFT CODE:
Fifth Third Bank
Indianapolis, IN
***
Routing Number:
***
Account Number:
***
Reference:
***



EX-101.SCH 5 snwv-20220224.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 snwv-20220224_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number No Trading Symbol Flag EX-101.PRE 7 snwv-20220224_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 24, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 24, 2022
Entity Registrant Name SANUWAVE HEALTH, INC.
Entity Incorporation, State or Country Code NV
Entity File Number 000-52985
Entity Tax Identification Number 20-1176000
Entity Address, Address Line One 3360 MARTIN FARM RD
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Suwanee
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30024
City Area Code 770
Local Phone Number 419-7525
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001417663
XML 9 brhc10034648_8k_htm.xml IDEA: XBRL DOCUMENT 0001417663 2022-02-24 2022-02-24 false 3360 MARTIN FARM RD 0001417663 8-K 2022-02-24 SANUWAVE HEALTH, INC. NV 000-52985 20-1176000 Suite 100 Suwanee GA 30024 770 419-7525 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://sanuwave.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10034648_8k.htm brhc10034648_ex10-1.htm brhc10034648_ex4-1.htm brhc10034648_ex4-2.htm snwv-20220224.xsd snwv-20220224_lab.xml snwv-20220224_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10034648_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10034648_8k.htm" ] }, "labelLink": { "local": [ "snwv-20220224_lab.xml" ] }, "presentationLink": { "local": [ "snwv-20220224_pre.xml" ] }, "schema": { "local": [ "snwv-20220224.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "snwv", "nsuri": "http://sanuwave.com/20220224", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10034648_8k.htm", "contextRef": "c20220224to20220224", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://sanuwave.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10034648_8k.htm", "contextRef": "c20220224to20220224", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sanuwave.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-22-007528-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-007528-xbrl.zip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end